Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Ioannis Gounaris - Executive Medical Director - Merck Group | LinkedIn
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. - Abstract - Europe PMC
Application of ARID1A to murine formalin-fixed... | F1000Research
Natasha LeGresley (@tashlegr) / Twitter
Ioannis Gounaris's research works | Novartis, Basel and other places
Trabectedin for advanced soft tissue sarcomas: a single institution experience | Future Oncology
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
Ioannis Gounaris's research works | Novartis, Basel and other places
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study | PLOS Medicine
400+ "Gounaris" profiles | LinkedIn
Trastuzumab-associated cardiac events in the Persephone trial | British Journal of Cancer
Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma
De-grading Petition - Disabled Students' Campaign
CRUK Cambridge Institute ar Twitter: "A huge congratulations to Dr Oscar Rueda on his new position at the @MRC_BSU @Cambridge_Uni! Oscar has been in our @CaldasLab working on the Personalised Breast Cancer
Trabectedin for advanced soft tissue sarcomas: a single institution experience
Ioannis Gounaris's research works | Novartis, Basel and other places
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer
Ioannis Gounaris's research works | Novartis, Basel and other places
Ovarian clear cell carcinoma—bad endometriosis or bad endometrium? - Gounaris - 2011 - The Journal of Pathology - Wiley Online Library
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals
